Citations

Clear

4847 citation(s) found for "Yu, Eric".

Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET
Stonnington, Cynthia M. , Chen, Yinghua , Savage, Cary R. , Lee, Wendy , Bauer, Robert, Sharieff, Sameen, Alexander, Gene E. , Caselli, Richard J. , Reiman, Eric M. , Locke, Dona E.C. , Thiyyagura, Pradeep , Chen, Kewei

Mayo Clinic

Journal of Alzheimer’s Disease | April 6, 2018 | Volume: 63 | Issue: 2 | Pages: 603-615

10.3233/jad-170852 | PMID 29630550 Get It

Background: Brain imaging measurements can provide evidence of possible preclinical Alzheimer’s disease (AD). Their ability to predict individual imminent clinical conversion remains unclear. Objective: To investigate the ability of pre-specified volumetric magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) measurements to predict which cognitively unimpaired older participants would subsequently progress to amnestic mild cognitive impairment (aMCI) within 2 years. Methods: From an apolipoprotein E4 (APOE4) enriched prospective cohort study, 18 participants subsequently progressed to the clinical diagnosis of aMCI or probable AD dementia within 1.8±0.8 years (progressors); 20 participants matched for sex, age, education, and APOE allele dose remained cognitively unimpaired for at least 4 years (nonprogressors). A complementary control group not matched for APOE allele dose included 35 nonprogressors. Groups were compared on baseline FDG-PET and MRI measures known to be preferentially affected in the preclinical and clinical stages of AD and by voxel-wise differences in regional gray matter volume and glucose metabolism. Receiver Operating Characteristic, binary logistic regression, and leave-one-out procedures were used to predict clinical outcome for the a priori measures. Results: Compared to non-progressors and regardless of APOE-matching, progressors had significantly reduced baseline MRI and PET measurements in brain regions preferentially affected by AD and reduced hippocampal volume was the strongest predictor of an individual’s imminent progression to clinically significant memory decline (79% sensitivity/78% specificity among APOE-matched cohorts). Conclusion: Regional MRI and FDG-PET measurements may be useful in predicting imminent progression to clinically significant memory decline.
Long-Term Outcomes of Glenohumeral Arthrodesis
Wagner, Eric R. , McLaughlin, Richard J. , Sarfani, Shumaila , Cofield, Robert H. , Sperling, John W. , Elhassan, Bassem T. , McLaughlin, Richard, Sanchez-Sotelo, Joaquin, Wagner, Eric R , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Bone and Joint Surgery | April 4, 2018 | Volume: 100 | Issue: 7 | Pages: 598-604

10.2106/jbjs.17.00428 | PMID 29613929 Get It

Background: Glenohumeral arthrodesis is associated with a high rate of complications. Although patients experience reasonable pain relief and shoulder stability, they experience marked limitations in their upper-extremity function. The purpose of this study was to examine the clinical outcomes of glenohumeral arthrodesis. Methods: Twenty-nine patients with 29 affected shoulders underwent primary glenohumeral arthrodesis between 1992 and 2009. Surgical indications included rotator cuff arthropathy and pseudoparalysis (n = 7), neurologic injuries (n = 12), chronic infection (n = 3), recurrent dislocations (n = 3), and proximal humeral or shoulder girdle tumors (n = 4). Surgical fixation techniques included plates and screws in 18 patients and screws only in 11 patients. Results: All patients were examined, with a mean follow-up of 12 years (range, 2 to 22 years). Twelve patients (41%) had postoperative complications, including 6 periprosthetic fractures, 7 nonunions, and 3 infections. Eleven patients (38%) required additional surgical procedures after arthrodesis, including revision internal fixation to achieve glenohumeral fusion after nonunions (n = 7), irrigation and debridement with antibiotic treatment for deep infections (n = 2), open reduction and internal fixation to treat fracture (n = 2), and implant removal to treat symptomatic patients (n = 3). Patients experienced reasonable overall pain relief. The mean postoperative scores were 35 points for the Subjective Shoulder Value, 58 points for the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, and 54 points for the Short Form-36. Eighty-seven percent of patients reported postoperative limitations. Patients with neurologic injuries had worse functional outcomes, and an arthrodesis position of ≥25° yielded better functional outcomes. Conclusions: Glenohumeral arthrodesis is associated with a high rate of patients with complications (41%). Although patients experience reasonable pain relief and shoulder stability, they experience marked limitations in their upper-extremity function. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Yang, Jingxuan , Zhang, Yuqing , Zhou, Zhijun , Cui, Xiaobo , Zhang, Liyang , Fung, Kar‐Ming , Zheng, Wei , Allard, Felicia D. , Yee, Eric U. , Ding, Kai , Wu, Huanwen , Liang, Zhiyong , Fernández-Zapico, Martín E. , Bronze, Michael S. , Morris, Katherine T. , Postier, Russell G., Yang, Jing , Li, Min , Yang, Jingxuan , Allard, Felicia D , Yee, Eric U , Liu, Mingyang , Zheng, Lei , Li, Yiping , Houchen, Courtney W.

Mayo Clinic

Clinical Cancer Research | April 3, 2018 | Volume: 24 | Issue: 13 | Pages: 3186-3196

10.1158/1078-0432.ccr-18-0263 | PMID 29615456 Get It

Abstract Purpose: ZIP4 is overexpressed in human pancreatic cancer and promotes tumor growth. However, little is known about the role of ZIP4 in advanced stages of this dismal neoplasm. Our goal is to study the underlying mechanism and define a novel signaling pathway controlled by ZIP4-modulating pancreatic tumor metastasis. Experimental Design: The expression of ZIP4, ZO-1, claudin-1, and ZEB1 in human pancreatic cancer tissues, genetically engineered mouse model, xenograft tumor model, and pancreatic cancer cell lines were examined, and the correlations between ZIP4 and those markers were also analyzed. Functional analysis of ZO-1, claudin-1, and ZEB1 was investigated in pancreatic cancer cell lines and orthotopic xenografts. Results: Genetic inactivation of ZIP4 inhibited migration and invasion in pancreatic cancer and increased the expression of ZO-1 and claudin-1. Conversely, overexpression of ZIP4 promoted migration and invasion and increased the expression of ZEB1 and downregulation of the aforementioned epithelial genes. ZIP4 downregulation of ZO-1 and claudin-1 requires the transcriptional repressor ZEB1. Further analysis demonstrated that ZIP4-mediated repression of ZO-1 and claudin-1 leads to upregulation of their targets FAK and Paxillin. Silencing of ZIP4 caused reduced phosphorylation of FAK and Paxillin, which was rescued by simultaneous blocking of ZO-1 or claudin-1. Clinically, we demonstrated that ZIP4 positively correlates with the levels of ZEB1 and inversely associates with the expression of ZO-1 and claudin-1. Conclusions: These findings suggest a novel pathway activated by ZIP4-controlling pancreatic cancer invasiveness and metastasis, which could serve as a new therapeutic target for this devastating disease. Clin Cancer Res; 24(13); 3186–96. ©2018 AACR.
Developing drugs for treatment of atopic dermatitis in children (≥3 months to
Siegfried, Elaine C. , Jaworski, Jennifer C., Eichenfield, Lawrence F. , Altman, Emily , Arena, Charles, Block, Julie, Boguniewicz, Mark , Chen, Suephy C. , Hanna, Diane , Horii, Kimberly A., Hultsch, Thomas , Lio, Peter , Milner, Joshua D. , Omachi, Theodore A. , Schneider, Lynda C. , Sidbury, Robert , Smith, Timothy W. , Sugarman, Jeffrey, Taha, Sharif, Tofte, Susan, Tollefson, Megha M. , Tom, Wynnis L. , Whitney, Lucinda , Zane, Lee T., Tollefson, Megha, Paller, Amy S. , Hebert, Adelaide Ann , Simpson, Eric Lawrence , Blauvelt, Andrew , Cordoro, Kelly M. , Lee, James , Leung, Donald Y.M. , Schneider, Christine B. , Sugarman, Jeffrey, West, Dennis Paul

Mayo Clinic

Pediatric Dermatology | March 30, 2018 | Volume: 35 | Issue: 3 | Pages: 303-322

10.1111/pde.13452 | PMID 29600515 Get It

AbstractAtopic dermatitis is the most common chronic skin disease, and it primarily affects children. Although atopic dermatitis (AD) has the highest effect on burden of skin disease, no high‐level studies have defined optimal therapy for severe disease. Corticosteroids have been used to treat AD since the 1950s and remain the only systemic medication with Food and Drug Administration approval for this indication in children, despite published guidelines of care that recommend against this option. Several clinical trials with level 1 evidence have supported the use of topical treatments for mild to moderate atopic dermatitis in adults and children, but these trials have had little consistency in protocol design. Consensus recommendations will help standardize clinical development and trial design for children. The Food and Drug Administration issues guidance documents for industry as a source for “the Agency's current thinking on a particular subject.” Although they are nonbinding, industry considers these documents to be the standard for clinical development and trial design. Our consensus group is the first to specifically address clinical trial design in this population. We developed a draft guidance document for industry, Developing Drugs for Treatment of Atopic Dermatitis in Children (≥3 months to <18 years of age). This draft guidance has been submitted to the Food and Drug Administration based on a provision in the Federal Register (Good Guidance Practices).
Impact of multi- versus single finger proximal interphalangeal joint arthroplasty: analysis of 249 fingers treated in 15 years
Srnec, Jason J. , Wagner, Eric R. , Rizzo, Marco , Wagner, Eric R

Mayo Clinic

Journal of Hand Surgery (European Volume) | March 29, 2018 | Volume: 43 | Issue: 5 | Pages: 524-529

10.1177/1753193418765691 | PMID 29595086 Get It

We retrospectively reviewed and compared the outcomes and complications associated with 81 single digit and 168 multi-digit proximal interphalangeal joint arthroplasties performed from 1998 to 2012 in 136 patients. Clinical outcomes were assessed with an average follow-up of 5.3 years for single digit and 5.9 years for multi-digit proximal interphalangeal joint arthroplasty. Comparing single versus multi-digit proximal interphalangeal joint arthroplasty, the reoperation-free survival was 67% and 68% at 5 years and 56% and 67% at 10 years, respectively. Furthermore, in comparison of single versus multi-digit proximal interphalangeal joint arthroplasty, the revision-free survival was 80% and 86% at 5 years and 80% and 85% at 10 years, respectively. Given the similar, or even slightly improved, rates of complications, reoperation, and revision surgery, proximal interphalangeal joint arthroplasty performed on multi-digits results in no worse outcomes compared with single digit proximal interphalangeal joint arthroplasty. Level of evidence: IV
P4472Targeted sequencing of 80 pharmacogenes reveals evidence for pleiotropic effects on serum LDL cholesterol levels
Nikroo, Nikta Dadkhah, Austin, Erin , Li, R. , Robertson, Peggy D., Stallings, Sarah , Larson, Eric B. , Linneman, James G., Jarvik, G.P., Crosslin, David R. , Schaid, Daniel J. , Network, eMERGE, Safarova, Maya , Andrade, Mariza de , Carrell, David , Bielinski, Suzette J. , Kullo, Iftikhar J. , Network, eMERGE

Mayo Clinic

European Heart Journal | March 29, 2018 | Volume: 38 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehx504.p4472 Get It

Open Microvascular Decompression
Pan, James , Kim, Lily H. , Ho, Allen L. , Sussman, Eric S. , Pendharkar, Arjun V. , Burns, Terry C. , Burns, Terry C

Mayo Clinic

Advances in Medical Diagnosis, Treatment, and Care | March 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: 70-103

10.4018/978-1-5225-5349-6.ch004 Get It

Microvascular decompression (MVD) is a neurosurgical procedure used to treat various neuralgias of the cranial nerves. The clinical presentation, natural history, pathophysiology, and medical management of trigeminal neuralgia, hemifacial spasm, glossopharyngeal neuralgia, and nervus intermedius neuralgia is reviewed. A thorough discussion on the retrosigmoid approach for decompression of cranial nerves is presented, along with newer techniques and controversies on adjuvant therapies and neuromonitoring. The surgical outcomes of MVD are discussed, along with alternative techniques to open MVD.
A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn’s Disease: Progress Made and Future Directions
Dozois, Eric J. , Lightner, Amy L. , Wang, Zhen , Zubair, Abba C.

Mayo Clinic

Diseases of the Colon & Rectum | March 25, 2018 | Volume: 61 | Issue: 5 | Pages: 629-640

10.1097/dcr.0000000000001093 | PMID 29578916 Get It

BACKGROUND: There has been a surge in clinical trials studying the safety and efficacy of mesenchymal stem cells for the treatment of perianal Crohn’s disease. OBJECTIVE: The purpose of this work was to systematically review the literature to determine safety and efficacy of mesenchymal stem cells for the treatment of refractory perianal Crohn’s disease. DATA SOURCES: Sources included PubMed, Cochrane Library Central Register of Controlled Trials, and Embase. STUDY SELECTION: Studies that reported safety and/or efficacy of mesenchymal stem cells for the treatment of perianal Crohn’s disease were included. Two independent assessors reviewed eligible articles. INTERVENTION: The study intervention was delivery of mesenchymal stem cells to treat perianal Crohn’s disease. MAIN OUTCOMES MEASURES: Safety and efficacy of mesenchymal stem cells used to treat perianal Crohn’s disease were measured. RESULTS: Eleven studies met the inclusion criteria and were included in the systematic review. Three trials with a comparison arm were included in the meta-analysis. There were no significant increases in adverse events (OR = 1.07 (95% CI, 0.61–1.89); p = 0.81) or serious adverse events (OR = 0.53 (95% CI, 0.28–0.98); p = 0.04) in patients treated with mesenchymal stem cells. Mesenchymal stem cells were associated with improved healing as compared with control subjects at primary end points of 6 to 24 weeks (OR = 3.06 (95% CI, 1.05–8.90); p = 0.04) and 24 to 52 weeks (OR = 2.37 (95% CI, 0.90–6.25); p = 0.08). LIMITATIONS: The study was limited by its multiple centers and heterogeneity in the study inclusion criteria, mesenchymal stem cell origin, dose and frequency of delivery, use of scaffolding, and definition and time point of fistula healing. CONCLUSIONS: Although there have been only 3 trials conducted with control arms, existing data demonstrate improved efficacy and no increase in adverse or serious adverse events with mesenchymal stem cells as compared with control subjects for the treatment of perianal Crohn’s disease.